Literature DB >> 29571839

Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014).

M A Pfaller1, P R Rhomberg2, M D Huband2, R K Flamm2.   

Abstract

Omadacycline is an aminomethylcycline with in vitro activity against many gram-negative pathogens. Omadacycline and comparators were tested against Enterobacteriaceae from urinary tract infections (UTIs) selected from a 2014 global surveillance program and compared to results of isolates from 2010 surveillance. The omadacycline MIC50/90 for Enterobacteriaceae collected during 2014 was 2/≥8 μg/mL (1/4 μg/mL minus Proteus, Providencia, and Morganella spp.). The MIC50/90 for E. coli was 1/2 μg/mL, similar to that in 2010 (MIC50/90, 0.5/2 μg/mL). The MICs for 91.7% of Klebsiella spp. isolates in 2014 (89.7%, 2010) were ≤4 μg/mL. In 2010 and 2014, a total of 100.0% and 95.8% of ESBL screen-positive (SP) phenotype E. coli and 73.9% and 75.0% of ESBL SP Klebsiella spp., respectively, exhibited MIC values at ≤4 μg/mL. Omadacycline was active against UTI-causing Enterobacteriaceae isolates from NA and EU. Further study of omadacycline to treat UTIs caused by Enterobacteriaceae may be indicated.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Enterobacteriaceae; Omadacycline; Urinary tract infections

Mesh:

Substances:

Year:  2018        PMID: 29571839     DOI: 10.1016/j.diagmicrobio.2018.01.019

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  8 in total

1.  In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018.

Authors:  Dong Dong; Yonggui Zheng; Qingqing Chen; Yan Guo; Yang Yang; Shi Wu; Demei Zhu; Daniel Deng; Patricia A Bradford; Harald Reinhart; Fupin Hu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-04-30       Impact factor: 3.267

2.  Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.

Authors:  Michael A Pfaller; Michael D Huband; Dee Shortridge; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 3.  Omadacycline.

Authors:  Danial E Baker
Journal:  Hosp Pharm       Date:  2019-01-22

Review 4.  Critical analysis of antibacterial agents in clinical development.

Authors:  Ursula Theuretzbacher; Karen Bush; Stephan Harbarth; Mical Paul; John H Rex; Evelina Tacconelli; Guy E Thwaites
Journal:  Nat Rev Microbiol       Date:  2020-03-09       Impact factor: 60.633

Review 5.  Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.

Authors:  George G Zhanel; Jenine Esquivel; Sheryl Zelenitsky; Courtney K Lawrence; Heather J Adam; Alyssa Golden; Rachel Hink; Liam Berry; Frank Schweizer; Michael A Zhanel; Denice Bay; Philippe R S Lagacé-Wiens; Andrew J Walkty; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

6.  Efficacy of Omadacycline against Escherichia coli in a Mouse Urinary Tract Infection Model.

Authors:  Kavindra V Singh; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

7.  In vitro activity of omadacycline and levofloxacin against Escherichia coli, Klebsiella pneumoniae and Staphylococcus saprophyticus in human urine supplemented with calcium and magnesium.

Authors:  Paul Pagano; Andrea Marra; Dean Shinabarger; Chris Pillar
Journal:  J Antimicrob Chemother       Date:  2020-08-01       Impact factor: 5.790

8.  The efficacy and safety of omadacycline in treatment of acute bacterial infection: A systemic review and meta-analysis of randomized controlled trials.

Authors:  Shao-Huan Lan; Shen-Peng Chang; Chih-Cheng Lai; Li-Chin Lu; Chien-Ming Chao
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.